SCHEMBL2545557

SCHEMBL2545557

Cc1ccc(P(C(C)(C)C)C(C)(C)C)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 6/20 0.44
TDP1 Q9NUW8 2/20 0.44
TSHR P16473 3/20 0.43
ALDH1A1 P00352 6/20 0.35
CA2 P00918 2/20 0.35
CA1 P00915 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
LMNA P02545 3/20 0.32
PKM P14618 2/20 0.32
HTT P42858 2/20 0.32
ATM Q13315 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
HPGD P15428 1/20 0.32
NLRP1 Q9C000 1/20 0.32
MEN1 O00255 1/20 0.32
NTSR1 P30989 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17239684 0.91 TSHR (0.37) ACHETDP1TSHRCES2CES1
SCHEMBL2557952 0.88
SCHEMBL30093072 0.80 KIF11 (0.32)
SCHEMBL2550429 0.78 LMNA (0.44) TDP1TSHRLMNANPSR1HPGD
SCHEMBL18650061 0.78 ACHE (0.44) ACHETDP1TSHRALDH1A1CA2
SCHEMBL3833780 0.76 ESR1 (0.46) ACHETSHRALDH1A1CA2CA1
SCHEMBL2548631 0.76 TSHR (0.48) ACHETDP1TSHRALDH1A1CA2
SCHEMBL2546780 0.76 CYP2A6 (0.42) TDP1ALDH1A1HTTHPGDMEN1
SCHEMBL16866207 0.76 MAPT (0.42) ACHETDP1TSHRALDH1A1HPGD
SCHEMBL2550793 0.76 ACHE (0.39) ACHEALDH1A1CA2CA1CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3024836-B1 IMPROVED METHOD FOR THE PREPARATION OF CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES BAYER CROPSCIENCE AG (DE) 2018-07-11 EP claimed
US-20180093942-A1 PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-04-05 US claimed
US-9868694-B2 Process for preparing chlorinated biphenylanilides and biphenylanilines BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2018-01-16 US claimed
US-20160280635-A1 IMPROVED PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2016-09-29 US claimed
US-12213376-B2 Organic photoelectric conversion material SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2025-01-28 US disclosed
CN-114270556-B Organic photoelectric conversion material 住友化学株式会社 2024-03-29 CN disclosed
US-20220310939-A1 ORGANIC PHOTOELECTRIC CONVERSION MATERIAL SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2022-09-29 US disclosed
EP-4024486-A1 ORGANIC PHOTOELECTRIC CONVERSION MATERIAL SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2022-07-06 EP disclosed
CN-110741028-B Method for producing polymer compound 住友化学株式会社 2022-05-03 CN disclosed
CN-110003271-B Process for producing aromatic compound 住友化学株式会社 2022-05-03 CN disclosed
EP-3418284-A1 IMPROVED METHOD FOR THE PREPARATION OF CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES Bayer CropScience Aktiengesellschaft (DE) 2018-12-26 EP disclosed
EP-3024836-B1 IMPROVED METHOD FOR THE PREPARATION OF CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES BAYER CROPSCIENCE AG (DE) 2018-07-11 EP disclosed
US-20130012725-A1 PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST CHROMAFORA AB (SE) 2013-01-10 US disclosed
WO-2011123037-A1 A PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST CHROMAFORA AB (SE) 2011-10-06 WO disclosed
US-7847126-B2 prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example LANXESS DEUTSCHLAND GMBH (DE) 2010-12-07 US disclosed
EP-1354886-B1 Process for the preparation of tertiary phosphines SALTIGO GMBH (DE) 2009-08-26 EP disclosed
US-20070299273-A1 prepared by reacting phosphorus halide with organomagnesium compound in presence of copper compound; di(tert-butyl)phenylphosphonium tetrafluoroborate, for example LANXESS DEUTSCHLAND GMBH (DE) 2007-12-27 US disclosed
US-7230136-B2 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2007-06-12 US disclosed
US-20030229240-A1 Reacting phosphorus halide with organomagnesium compound in presence of copper compound LANXESS DEUTSCHLAND GMBH (DE) 2003-12-11 US disclosed
EP-1354886-A1 Process for the preparation of tertiary phosphines Bayer Aktiengesellschaft (DE) 2003-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093942-A1 PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES DDT, CBR3, MSRB3 ACHE 1349/4885TDP1 4011/4885TSHR 84/4885
US-20160280635-A1 IMPROVED PROCESS FOR PREPARING CHLORINATED BIPHENYLANILIDES AND BIPHENYLANILINES CYP2F1, CYP1A1, CYP4F12 ACHE 717/4885TDP1 3383/4885TSHR 661/4885
US-20130012725-A1 PROCESS FOR THE REDUCTION OF A TERTIARY PHOSPHINE OXIDE TO THE CORRESPONDING TERTIARY PHOSPHINE IN THE PRESENCE OF A CATALYST AND USE OF A TERTIARY PHOSPHINE FOR REDUCING A TERTIARY PHOSPHINE OXIDE IN THE PRESENCE OF A CATALYST PSPH, PNPO, PHOSPHO1 ACHE 154/4885TDP1 1944/4885TSHR 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.